Marco A. Maurtua

Marco A. Maurtua

Auto-generated profile, based on publicly available information

Marco A. Maurtua

Department of General Anesthesiology and Critical Care Medicine, Cleveland Clinic, Cleveland, OH 44195, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Journal of Neurosurgical Anesthesiology
Verified
Journal Article
Closed access
MMMarco A. Maurtua
Marco A. Maurtua
ADAnupa Deogaonkar
Anupa Deogaonkar
MBMohamed H. Bakri
Mohamed H. Bakri
EMEdward Mascha
Edward Mascha
JNJie Na
Jie Na
ASArmin Schubert
Armin Schubert
In neuroanesthesia practice, muscle relaxants may at times need to be avoided to facilitate intraoperative motor pathway monitoring. Our study's objective was to determine the optimal dose of remifentanil required to prevent movement after neurosurgical stimulation. After Institutional Review Board approval and written informed consent, 132 patients undergoing elective craniotomy randomly received one of 12 remifentanil dose regimens (0.10 to 0.21 microg/kg/min). Remifentanil was started before induction with propofol and succinylcholine. Anesthesia was maintained with isoflurane (0.6% end-tidal) in air/oxygen. During the study, movement was assessed on predetermined criteria by the anesthesiology, nursing, and neurosurgical teams. Heart rate and blood pressure were recorded every 5 minutes. We assessed the relationship between movement, hypotension, bradycardia, and dose using probit analysis and logistic regression. Sixty-five percent of the patients moved in response to surgical stimuli [95% confidence interval (CI): 49%-79%] at a remifentanil infusion rate of 0.10 microg/kg/min, and movement decreased to 21% (95% CI: 11-35) at 0.21 microg/kg/min. The probability of movement was 50% at an infusion rate (95% CI) of 0.13 (0.10 to 0.15) microg/kg/min remifentanil and decreased to 25% at an infusion rate of 0.19 (0.17 to 0.29) microg/kg/min. The probability of hypotension and bradycardia was 50% at 0.13 (0.10 to 0.15) microg/kg/min and 0.17 (0.15 to 0.21) microg/kg/min, respectively. Higher doses of remifentanil lessen the risk of movement in the absence of muscle relaxants with surgical stimulation for elective craniotomy. Hypotension and bradycardia were common at higher doses. Even at the maximum dose (0.21 mcg/kg/min) there was a 20% chance of movement. Adjunctive therapy is needed to ablate movement reliably, and to counteract the hypotensive effect of remifentanil. These findings may be helpful for clinicians administering remifentanil and isoflurane during procedures, where muscle relaxants may not be desirable.

1 May 2009 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
MMMarco A. Maurtua
Marco A. Maurtua
JCJuan P. Cata
Juan P. Cata
MMMargarita Martirena
Margarita Martirena
MDMillind Deogaonkar
Millind Deogaonkar
ARAli Rezai
Ali Rezai
ASArmin Schubert
Armin Schubert

1 October 2008 in International Journal of Obstetric Anesthesia
Verified
Journal Article
Closed access
MMM. Maurtua
M. Maurtua
ATA. Torres
A. Torres
VIV. Ibarra
V. Ibarra
GDG. DeBoer
G. DeBoer
JDJ. Dolak
J. Dolak

1 March 2007 in Anesthesiology
Verified
Journal Article
Open access
PDF file
MMMarco A. Maurtua
Marco A. Maurtua
DMDelia B. Maurtua
Delia B. Maurtua
AZAndrew Zura
Andrew Zura
DDD John Doyle
D John Doyle

1 August 2012 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
MMMarco A. Maurtua
Marco A. Maurtua
MFMichael Fernando
Michael Fernando
PFPatrick S. Finnegan
Patrick S. Finnegan
BMBehram Mehta
Behram Mehta
JWJiang Wu
Jiang Wu
DDDaniel Doyle
Daniel Doyle

1 February 2011 in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Verified
Journal Article
Closed access
PDF file
MMMarco A. Maurtua
Marco A. Maurtua
PFPatrick S. Finnegan
Patrick S. Finnegan
GDGlenn DeBoer
Glenn DeBoer